$ALT

Altimmune (NASDAQ:ALT) reported Phase II results for pemvidutide in alcohol use disorder. The WHO risk-drinking-level endpoint improved in 64.4% vs 34.8% on placebo (p=0.0049), and zero heavy drinking days increased with p=0.0066. PEth fell by 175.3 ng/mL vs unchanged on placebo (p=0.0001). Safety was generally tolerable; Phase III AUD discussions with regulators are next.

Altimmune said its RECLAIM Phase 2 trial of pemvidutide for moderate to severe alcohol use disorder met the primary endpoint, with 2.4 mg producing a statistically significant reduction in heavy drinking days per week versus placebo over 24 weeks (treatment effect 1.45 days). It also met secondary endpoints, and the company plans an End-of-Phase 2 meeting with the FDA. Shares rose 11.5% pre-open.

Altimmune Inc. (NASDAQ:ALT) shares rose 18% after it reported positive topline results from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder. The study met its primary endpoint with a statistically significant reduction in heavy drinking days versus placebo (4.20 vs 2.75 per week at week 24, p=0.0014). Secondary endpoints and safety data were also favorable, and the company plans an FDA End-of-Phase 2 meeting.

The article says the U.S. anti-obesity drug market is expanding, with the global GLP-1 market reaching $79B in 2025 and projected by Morgan Stanley to exceed $190B by 2035. It cites January 2026 oral Wegovy pill uptake and Medicare/Medicaid BALANCE plans to cap out-of-pocket costs at $50/month. It also notes DOJ scrutiny of compounded formulations and lists 10 stocks, including Altimmune (H.C. Wainwright cut ALT target to $20 from $25) and GSK.

Altimmune Inc (ALT) reported a strong cash position of approximately USD535 million as of April 2026, bolstered by a USD225 million public offering. Despite increased R&D and G&A expenses leading to a net loss of USD22.6 million in Q1 2026, the company's financial runway is secured through the Phase III MASH 52-week data readout in 2029. Pemvidutide, their lead drug candidate, has received Breakthrough Therapy designation, and its Phase II IMPACT trial showed promising efficacy, with Phase III trials aligned with regulatory feedback from the FDA and EMA.

Deep Track Capital, along with its affiliates Deep Track Biotechnology Master Fund, Ltd. and Deep Track Special Opportunities Fund, LP, and David Kroin, has reported a 9.99% beneficial ownership stake in Altimmune (ALT). This stake, amounting to 19,417,221 shares, includes common stock, pre-funded warrants, and warrants, all subject to a 9.99% maximum exercise limitation. The disclosure was made via a Schedule 13G filing as of April 30, 2026 and is based on 194,366,579 shares outstanding.

This article states that despite some recent positive share price movement, Altimmune insiders are still collectively down US$29k on their investments over the last year. This is primarily due to a significant share price decline, meaning recent share purchases by insiders have not yet compensated for previous losses.

Altimmune, Inc. director John Gill purchased 9,200 shares of common stock on the open market at a weighted average price of $3.4076 per share, totaling approximately $31,350. This transaction increases his direct holdings to 21,700 shares. The purchase, made in multiple trades between $3.4050 and $3.4080, signals a positive sentiment from an insider.

Altimmune's 48-week data on pemvidutide for MASH show improvements in fibrosis based on non-invasive test results. However, the data still raise questions regarding the overall fibrosis benefit. The company's presentation of this data is aimed at addressing ongoing doubts.

GAITHERSBURG, Md., Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ( Nasdaq: ALT ) , a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will ...